The use of long acting β2-agonists, alone or in combination with inhaled corticosteroids, in Chronic Obstructive Pulmonary Disease (COPD): A risk-benefit analysis

Pharmacology and Therapeutics

Volumn 130, Issue 2, 2011, Pages 114-143

  Cave, Alison C ^a   Hurst, Martin M ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

COPD; Inhaled corticosteroids; Long acting agonists; Lung function; Pneumonia; Risk benefit

Indexed keywords

ACETYLCHOLINE; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; COLECALCIFEROL; CORTICOSTEROID; DEXAMETHASONE; DIURETIC AGENT; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HYDROCORTISONE; IPRATROPIUM BROMIDE; MUSCARINIC AGENT; PLACEBO; PREDNISOLONE; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ANTIBIOTIC THERAPY; ARTHRALGIA; ASTHMA; BRONCHODILATATION; BRONCHOPNEUMOIA; CANDIDIASIS; CARDIOMYOPATHY; CARDIOTOXICITY; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; CUSHING DISEASE; DISEASE EXACERBATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; ECZEMA; EYE SWELLING; FORCED EXPIRATORY VOLUME; FRACTURE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GROWTH RETARDATION; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART RATE AND RHYTHM; HEART RIGHT VENTRICLE FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORTALITY; MUSCLE DISEASE; MUSCLE SPASM; NAUSEA; NONHUMAN; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; ETHANOLAMINES; HUMANS; MUSCARINIC ANTAGONISTS; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT;

EID: 79953658881     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.12.008     Document Type: Review

References (123)

1. Anzueto, A., Ferguson, G. T., Feldman, G., Chinsky, K., Seibert, A., Emmett, A., et al. (2009). Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. J COPD 6, 320-329.
2. Anzueto, A., Sethi, S., & Martinez, F. J. (2007). Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 4, 554-564. (Pubitemid 47547851)
3. Appleton, S., Poole, P., Veale, A., Lasserson, T. J., Chan, M. M., & Cates, C. J. (2007). Longacting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Libr 2, 1-84.
4. Au, D. H., Udris, E. M., Fan, V. S., Randall, C. J., McDonell, B. M., & Fihn, D. S. (2003). Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 123, 1964-1969. (Pubitemid 36706719)
5. Augusti, C., Rano, A., Filella, X., Gonzalez, J., Moreno, A., Xaubert, A., et al. (2003). Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 123, 488-498. (Pubitemid 36269435)
6. Balkissoon, R., & Make, B. (2008). A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 μg prn q4 hours to Flu/Sal 250/50 bid plus albuterol/ Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease. COPD 5, 221-227.
7. Barnes, P. J. (2006). How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 148, 245-254.
8. Barnes, P. J. (2008). Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 5, 857-864.
9. Barnes, P. J. (2009). Role of HDAC2 in the pathophysiology of COPD. Rev Adv 71, 1-9.
10. Barnes, N. C., Qiu, Y. -S., Pavord, I. D., Parker, D., Davis, P. A., Zhu, J., et al. (2006). Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173, 736-743.
11. Barnes, P. J., Shapiro, S. D., & Pauwels, R. A. (2003). Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22, 672-688. (Pubitemid 37258549)
12. Bhowmik, A., Seemungal, T., Sapsford, J., & Wedzicha, J. A. (2000). Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 55, 114-120. (Pubitemid 30245950)
13. Briggs, D. D. (2004). Chronic obstructive pulmonary disease overview: prevalence, prognosis, and treatment. JMCP 10, S3-S10.
14. Brightling, E., Monteiro, W., Ward, R., Parker, D., Morgan, M., et al. (2000). Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356, 1480-1485.
15. Bristow, M. R., Ginsburg, R., Umans, V., Fowler, M., Minobe, W., Rasmussen, R., et al. (1986). Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59, 297-309. (Pubitemid 17178124)
16. Bruttsche, M., Brutsche, I., Munawar, M., Langley, S., et al. (2000). Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 356, 556-561. (Pubitemid 30611861)
17. Burge, P., Calverley, P. M. A., Jones, W. P., Spencer, S., Anderson, A. J., & Maslen, T. K. (2000). Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320, 1297-1303. (Pubitemid 30245717)
18. Burge, S., & Wedzicha, J. A. (2003). COPD exacerbations: definitions and classifications. Eur Respir J 21(S41), 46S-53S.
19. Calverley, P. M. A., Anderson, J. A., B, C., Ferguson, G. T., Jenkins, C., Jones, P. W., et al. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Eng J Med 356, 775-789. (Pubitemid 46294610)
20. Calverley, P. M. A., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., & Olsson, H. (2003a). Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22, 912-919. (Pubitemid 37540641)
21. Calverley, P. M. A., Burge, P. S., Spencer, S., Anderson, J. A., & Jones, P. W. (2003b). Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58, 659-664. (Pubitemid 36976273)
22. Calverley, P. M. A., Pauwels, R., Vestbo Jorgen, M. D., Jones, W. P. M. D., Pride, N., et al. (2003c). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361, 449-456. (Pubitemid 36173708)
23. Calverley, P. M. A., Spencer, S., Willits, L., Burge, P. S., & Jones, P. W. (2003d). Withdrawal from treatment as an outcome in the ISOLDE study of COPD*. Chest 124, 1350-1356.
24. Camilli, A. E., Robbins, D. R., & Lebowitz, M. D. (1991). Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 133, 795-800.
25. Campbell, M., Eliraz, A., Johansson, G., Tornling, G., Nihlen, U., Bengtsson, T., et al. (2005). Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 99, 1511-1520. (Pubitemid 41683932)
26. Cazzola, M., Hanania, N. A., Jones, W. P. M. D., Mahler, D. A., Make, B., Ohar, J., et al. (2008). It's about time-directing our attention toward modifying the course of COPD. Respir Med 102, 537-548.
27. Cazzola, M., Matera, M. G., Santangelo, G., Vinciguerra, A., Rossi, F., & D'Amato, G. (1995). Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 89, 357-362.
28. Cazzola, M., Santangelo, G., Piccolo, A., Salzillo, A., Matera, M. G., D'Amato, G., et al. (1994). Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 7, 103-107. (Pubitemid 24210802)
29. Celli, B., Thomas, N. E., Anderson, J. A., Ferguson, G. T., Jenkins, C., Jones, W. P. M. D., et al. (2008). Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178, 332-338.
30. Chapman, K. R., Arvidsson, P., Chuchalin, A. C., Dhillon, D. P., Faurshou, P., Goldstein, R., et al. (2002). The addition of salmeterol 50 mcg bid to anticholinergic treatment in patients with COPD: a randomised placebo controlled trial. Can Respir J 9, 178-185. (Pubitemid 34863635)
31. Chapman, K. R., Mannino, D. M., Soriano, J. B., Vermeire, P. A., Buist, A. S., Thun, M., et al. (2006). Series "TheGlobal Burden of Chronic Obstructive Pulmonary Disease". Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 27, 188-207. (Pubitemid 43092683)
32. 2-adrenoceptor-mediated responses in human lung mast cells. Br J Pharmacol 121, 717-722.
33. Cosio, B. G., Mann, B., Ito, K., Jazrawi, E., Barnes, P. J., Chung, K. F., et al. (2004a). Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 170, 141-147. (Pubitemid 38925159)
34. Cosio, B. G., Tsaprouni, L., Ito, K., Jazrawi, E., Adcock, I. M., & Barnes, P. J. (2004b). Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200, 689-695. (Pubitemid 39258317)
35. Crim, C., Calverley, P. M., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., et al. (2009). Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34, 641-647.
36. Dompeling, E., van Schayck, C. P., Molema, J., Akkermans, R., Folgering, H., van Grunsven, P. M., et al. (1992). A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1. Eur Respir J 5, 975-981.
37. Donaldson, G. C., Seemungal, T., Bhowmik, A., & Wedzicha, J. A. (2002). Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57, 847-852. (Pubitemid 35178607)
38. Drummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J., & Fan, E. (2008). Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300, 2407-2416.
39. Esmailpour, N., Hogger, P., Rabe, K. F., Heitmann, U., Nakashima, M., & Rohdewald, P. (1997). Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 10, 1499.
40. Ferguson, G. T., Anzueto, A., Fei, R., Emmett, A., Knobil, K., & Kalberg, C. (2008). Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 102, 1099-1108.
41. Ferguson, T., Gary, M. D., Funk-Brentano, C., Fischer, T., Darken, P., & Reisner, C. (2003). Cardiovascular safety of salmeterol in COPD. Chest 123, 1817-1824.
42. Fishman, W. H., Heiman, M., Karpenos, A., Ooi, W. L., Mitzner, A., Goldkorn, R., et al. (1996). Twenty-four-hour ambulatory electrocardiography in elderly subjects: prevalence of various arrhythmias and prognostic implications (report from the Bronx Longitudinal Aging Study). Am Heart J 132, 297-302. (Pubitemid 26292394)
43. Fletcher, C. M., Elmes, P. C., & Wood, C. H. (1959). The significance of respiratory symptoms and diagnosis of chronic bronchitis in a working population. BMJ 8, 257-266.
44. Gan, W. Q., Man, S. F. P., Senthilselvan, A., & Sin, D. D. (2004). Chronic Obstructive Pulmonary Disease, association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59, 574-580. (Pubitemid 38901515)
45. Giembycz, M. A., Kaur, M., Leigh, R., & Newton, R. (2008). A Holy Grail of asthma management: toward understanding how long-acting B2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 153, 1090-1104. (Pubitemid 351415494)
46. GOLD guidelines (2009). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd. com.
47. Gosens, R., Zaagsma, J., Meurs, H., & Halayko, A. (2006). Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 7, 73.
48. Gross, N. J., & Skorodin, M. S. (1984). Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 311, 421-425. (Pubitemid 14058252)
49. Grove, A., & Lipworth, B. (1996). Effects of prior treatment with salmeterol and formoterol on airway and systemic B2 responses to fenoterol. Thorax 51, 585-589. (Pubitemid 126788218)
50. GSK Clinical Trial (2000). A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250 mcg BID, 500 mcg BID, and placebo BID via the Diskus in subjects with chronic obstructive pulmonary disease (COPD). http://gsk-clinicalstudyregister.com/files/pdf/1231.pdf.
51. Hanania, N. A., Darken, P., Horstman, D., Reisner, C., Lee, B., Davis, S., et al. (2003). The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD*. Chest 124, 834-843. (Pubitemid 37123298)
52. Hankinson, J. L., Odencrantz, J. R., & Fedan, K. B. (1999). Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159, 179-187. (Pubitemid 29036522)
53. Hanrahan, J. P., Grogan, D. R., Baumgartner, R. A., Wilson, A., Cheng, H., Ziometbaum, P. J., et al. (2008). Arrhythmias in patients with chronic obstructive pulmonary disease (COPD) occurrence frequency and the effect of treatmentwith the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine 87, 319-328.
54. Hauben, M., & Zhou, X. (2009). Quantitative methods in pharmacovigilance. Focus on signal detection. Drugs Saf 26, 159-186.
55. Ito, K., Ito, M., Elliott, W. M., Cosio, B., Caramori, G., Kon, O. M., et al. (2005). Decreased histone deacetylase activity in chronic obstructive pulmonary disease. New Eng J Med 352, 1967-1976. (Pubitemid 40638367)
56. Ito, K., Lim, S., Caramori, G., Cosio, B. G., Chung, K. F., Adcock, I. M., et al. (2002). A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99, 8921-8926. (Pubitemid 34693659)
57. Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., et al. (2006). Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-{kappa}B suppression. J Exp Med 203, 7-13. (Pubitemid 43139638)
58. Jarad, N. A., Wedzicha, J. A., Burge, P. S., & Calverley, P. M. A. (1999). An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 93, 161-166.
59. Jenkins, C., Jones, P., Calverley, P., Celli, B., Anderson, J., Ferguson, G., et al. (2009). Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 10, 59.
60. Johannessen, A., Lehmann, S., Omenaas, E. R., Eide, G. E., Bakke, P. S., & Gulsvik, A. (2006). Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 173, 1316-1325. (Pubitemid 43900705)
61. Jones, P. W. (2005). St George's Respiratory Questionnaire: MCID. COPD 2, 75-79.
62. Jones, W. P. M. D., & Agusti, A. (2006). Outcomes and markers in the assessment of Chronic Obstructive Pulmonary Disease. Eur Respir J 27, 822-832.
63. Jones, P. W., Quirk, F. H., BaveystockC, M., & Littlejohns, P. (1992). A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145, 1321-1327.
64. Kalavantavanich, K., & Schramm, C. M. (2000). Dexamethasone protentiates high-affinity B-agonist binding and GsQ protein expression in airway smooth muscle. Am J Physiol Lung Cell 278, L1101-L1106. (Pubitemid 30351068)
65. Kallen, A., & Thorsson, L. (2003). Drug deposition analysis: a comparison between budesonide and fluticasone. J Pharmacokinet Phar 30, 239-256. (Pubitemid 37352522)
66. Kardos, P., Wencker, M., Glaab, T., & Vogelmeier, C. (2006). Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175, 144-149.
67. Kaur, M., Chivers, J. E., Giembycz, M. A., & Newton, R. (2008). Long-acting B2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 73, 203-214. (Pubitemid 350294211)
68. Keene, O. N., Celli, B., Anderson, J. A., Ferguson, G. T., Jenkins, C. R., Jones, P. W., et al. (2009a). Lung function decline in COPD trials. Eur Respir J 33, 708-709.
69. Keene, O. N., Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B., Ferguson, G. T., et al. (2009b). Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J 34, 1018-1023.
70. Korosec, M., Novak, R. D., Myers, E., Skowronski, M., & McFadden, E. R. (1999). Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med, 209-213. (Pubitemid 29421585)
71. Krieger, B. P. (2009). Hyperinflation and intrinsic positive end-expiratory pressure: less room to breathe. Respiration 77, 344-350.
72. Lapperre, T. S., Snoeck-Stroband, J. B., Gosman, M. M., Jansen, D. F., van, S. A., Thiadens, H. A., et al. (2009). Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 151, 517-527.
73. Lemaitre, R. N., Siscovick, D. S., Psaty, B. M., Pearce, R. M., Raghunathan, T. E., Whitsel, E. A., et al. (2002). Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med 113, 711-716. (Pubitemid 36044695)
74. Mak, J. C. W., Nishikawa, M., Shirasaki, H., Miyayasu, K., & Barnes, P. J. (1995). Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo. J Clin Invest 96, 99-106.
75. Mancini, J. G. B., Etminan, M., Zhang, B., Levesque, L. E., Fitzgerald, M., & Brophy, J. M. (2006). Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47, 2554-2560. (Pubitemid 43866389)
76. Manolio, T. A., Furberg, C. D., Rautaharju, P. M., Siscovick, D., Newman, A. B., Borhani, N. O., et al. (1994). Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. J Am Coll Cardiol 23, 916-925. (Pubitemid 24090878)
77. Molimard, M., Naline, E., Zhang, Y., Le Gros, V., Begaud, B., & Advenier, C. (1998). Long- and short acting B2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J 11, 583-588. (Pubitemid 28194847)
78. Naline, E., Zhang, Y., Qian, Y., Mairon, N., Anderson, G. P., Grandordy, B., et al. (1994). Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 7, 914-920. (Pubitemid 24153592)
79. Nannini, L., Cates, C. J., Lasserson, T. J., & Poole, P. (2008a). Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease (review). Cochrane Libr, 1-108.
80. Nannini, L., Cates, C. J., Lasserson, T. J., & Poole, P. (2008b). Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4, 1-96.
81. National Clinical Guideline Centre (2010). Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. http://guidance.nice.org.uk/CG101/Guidance/pdf/ English.
82. Newton, M. F., O'Donnell, D. E., & Forkert, L. (2002). Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation*. Chest 121, 1042-1050. (Pubitemid 34280421)
83. Nie, M., Knox, A. J., & Pang, L. (2005). β2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J Immunol 175, 478-486. (Pubitemid 40884352)
84. Nisar, M., Walshaw, M., Earis, J. E., Pearson, M. G., & Calverley, P. M. A. (1990). Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 45, 190-194.
85. Nishimura, K., Izumi, T., Tsukino, M., & Oga, T. (2002). Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121, 1434-1440. (Pubitemid 34499652)
86. Noord Van, J. A., Munck de, D. R. A. J., Bantje, Th. A., Hop, W. C. J., Akveld, M. L. M., & Bommer, A. M. (2000). Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the addictive effect of ipratropium. Eur Respir J 15, 878-885. (Pubitemid 30321844)
87. O'Donnell, D. E., & Laveneziana, P. (2006). Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 15, 61-67. (Pubitemid 47035703)
88. O'Donnell, D. E., Voduc, N., Fitzpatrick, M., & Webb, K. A. (2004). Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24, 86-94. (Pubitemid 39029073)
89. O'Reilly, J., Jones, M. M., Parnham, J., Lovibond, K., & Rudolf, M. (2010). Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 340, c3134.
90. Partridge, M. R., Schuermann, W., Beckman, O., Persson, T., & Polanowski, T. (2009). Effects on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 3, 1-11.
91. Pellegrino, R., Decramer, M., van Schayck, C. P. O., Dekhuijzen, P. N. R., Troosters, T., van Herwaarden, C., et al. (2005a). Quality control of spirometry: a lesson from the BRONCUS trial. Eur Respir J 26, 1104-1109. (Pubitemid 41829944)
92. Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R. O., Burgos, F., Casaburi, R., et al. (2005b). Interpretative strategies for lung function tests. Eur Respir J 26, 948-968. (Pubitemid 41632054)
93. Petty, T. L. (2000). Scope of the COPD problem in North America*. Chest 117, 326S-331S.
94. Rabe, F. K. (2007). Treating COPD-the TORCH trial, P values, and the dodo. New Eng J Med, 851-855.
95. Reilly, J., Jones, M. M., Parnham, J., Lovibond, K., & Rudolf, M. (2010). Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 340, c3134.
96. Rennard, S. I. (2006). Chronic obstructive pulmonary disease linking outcomes and pathobiology of disease modification. Proc Am Thorac Soc 3, 276-280.
97. Rennard, S. I., Tashkin, D. P., McElhattan, J., Goldman, M., Ram, S., Martin, U. J., et al. (2009). Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69, 549-565.
98. Rodrigo, G. J., Castro-Rodriguez, J. A., & Plaza, V. (2009). Safety and efficacy of combined long-acting β-agonists and inhaled corticosteroids vs long-acting β-agonists monotherapy for stable COPD. Chest 136, 1029-1038.
99. Salpeter, S., Ormiston, T., & Salpeter, E. (2004). Cardiovascular effects with B-agonists in patients with asthma and COPD. Chest 125, 2309-2321. (Pubitemid 38796452)
100. Schramm, C. M. (2000). β-Adrenergic relaxation of rabbit tracheal smooth muscle: a receptor deficit that improves with corticosteroid administration. J Pharmacol Exp Ther 292, 280-287.
101. Seemungal, T. A. R., Donaldson, G. C., BHOWMIK, A. N. G. S., Jeffries, D. J., &Wedzicha, J. A. (2000). Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161, 1608-1613.
102. Sin, D. D., & Man, S. F. P. (2003). Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107, 1514-1519. (Pubitemid 36378490)
103. Sin, D. D., Man, S. F. P., Marciniuk, D., Ford, J. G., Fitzgerald, M., Wong, E., et al. (2008). The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177, 1207-1214. (Pubitemid 351860929)
104. Sin, D. D., Tashkin, D., Zhang, X., Radner, F., Sjöbring, U., Thorén, A., et al. (2009). Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 374, 712-719.
105. Sin, D. D., Wu, L., Anderson, A., Julie, M. A., & Anthonisen, N. (2005). Chronic obstructive pulmonary disease, inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60, 992-997. (Pubitemid 41705466)
106. Singh, D., Brooks, J., Hagan, G., Cahn, A., & O'Connor, B. (2008). Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63, 592-598.
107. Singh, D., Houghton, W., Daley-Yates, Kirby, S., & Woodcock, A. (2002). Pharmacokinetics and systemic effects of inhaled fluticasone propionate in Chronic Obstructive Pulmonary Disease. J Clin Pharmacol 55, 375-381.
108. Soler-Cataluna, J. J., Martinez-Garcia, M. A., Sanchez, P. R., Salcedo, E., Navarro, M., & Ochando, R. (2005). Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60, 925-931. (Pubitemid 41598207)
109. Soriano, J. B., Sin, D. D., Zhang, X., Camp, P., Anderson, A. J., Anthonisen, N., et al. (2007). A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 131, 682-689. (Pubitemid 46446857)
110. Soriano, J. B., Vestbo Jorgen, M. D., Pride, N., Kirl, V., Maden, C., & Maier, W. (2002). Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20, 819-825. (Pubitemid 35175115)
111. Sovani, M., Whale, C., & Tattersfield, A. E. (2004). A benefit-risk assessment of inhaled long-acting B2-agonists in the management of obstructive pulmonary disease. Drug Saf 27, 689-715. (Pubitemid 39158991)
112. Stockley, R. A., Whitehead, P., & Williams, K. M. (2006). Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 7, 147.
113. Suissa, S. (2006). Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173, 842-846.
114. Suissa, S. (2008). Lung function decline in COPD trials: bias from regression to the mean. Eur Respir J 32, 829-831.
115. Suissa, S., Ernst, P., Vandemheen, K. L., & Aaron, S. D. (2008). Methodological issues in therapeutic trials of COPD. Eur Respir J 31, 927-933.
116. Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., et al. (2003). Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21, 74-81. (Pubitemid 36150304)
117. Tashkin, D. P., Bartolome, C., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., et al. (2008a). A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New Engl J Med 359, 1543-1554.
118. Tashkin, D. P., Rennard, S. I., Martin, P., Ramachandran, S., Martin, U. J., Silkoff, P. E., et al. (2008b). Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 14, 1975-2000.
119. Thorsson, L., Edsbacker, S., Kallen, A., & Lofdahl, C. -G. (2001). Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI and of budesonide via Turbohaler. Br J Clin Pharmacol 52, 529-538.
120. Vestbo, J., Anderson, W. J., Coxson, H. O., Crim, C., Dawber, F., Edwards, L., et al. (2008). Evaluation of COPD Longitudinally to identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 31, 869-873.
121. Wadbo, M., Lofdahl, C. -G., Larsson, K., Skoogh, B. E., Tornling, G., Arwestrom, E., et al. (2002). Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 20, 1138-1146. (Pubitemid 35331870)
122. Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., Stockley, R. A., et al. (2008). The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177, 19-26.
123. Xystrakis, E., Kusumakar, S., Boswell, S., Peek, E., Urry, Z., Richards, D. F., et al. (2006). Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 116, 146-155. (Pubitemid 43121799)